Plasminogen activator inhibitor-1 4G/5G genotype and residual venous occlusion following acute unprovoked deep vein thrombosis of the lower limb: A prospective cohort study.

BACKGROUND A recent study suggested that the plasminogen activator inhibitor (PAI)-1 4G/5G genotype may play a role in the resolution of deep vein thrombosis (DVT) after surgery. In the present study, we investigated the association between PAI-1 4G/5G genotype and the persistence of venous occlusion after acute idiopathic DVT of the lower limb. METHODS The PAI-1 4G/5G genotype was determined by real-Time PCR in 43 patients with unprovoked DVT of the lower limb. Residual venous occlusion was assessed by duplex sonography 1, 3, 6, 12 and 24months after the acute event. The PAI-1 Activity was determined by ELISA. RESULTS Ten patients (23%) were homozygous for 4G (4G/4G), 27 patients (63%) were heterozygous 4G/5G and 6 patients (14%) were homozygous for 5G (5G/5G). Residual venous occlusion (RVO) was found in 77%, 65%, 58%, 56% and 37% of the overall study population, at 1, 3, 6, 12 and 24months after acute DVT, respectively. The presence of residual venous occlusion at 1, 3, 6, 12 and 24months after acute unprovoked DVT did not differ significantly between genotypes, but age was associated with RVO. Plasma levels of PAI-1 activity correlated with body mass index but was not associated with genotypes in our study. CONCLUSION The PAI-1 4G/5G genotype was not a relevant predictor of persistent residual venous occlusion after idiopathic DVT, which however was associated with age.

[1]  E. Kruithof,et al.  Plasminogen activator inhibitors--a review. , 1988, Enzyme.

[2]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[3]  P. Reitsma,et al.  Risk Factor Profiles in Patients with Different Clinical Manifestations of Venous Thromboembolism: A Focus on the Factor V Leiden Mutation , 1996, Thrombosis and Haemostasis.

[4]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[5]  T. Wakefield,et al.  Dose-dependent thrombus resolution due to oral plasminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis , 2008, Thrombosis and Haemostasis.

[6]  Paweł Kiciński,et al.  Evaluation of Fibrinolytic Inhibitors: Alpha-2-Antiplasmin and Plasminogen Activator Inhibitor 1 in Patients with Obstructive Sleep Apnoea , 2016, PloS one.

[7]  D. Arveiler,et al.  Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[8]  A. Finn,et al.  4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia , 2005, European Journal of Pediatrics.

[9]  F. Rosendaal,et al.  Predictors of the post‐thrombotic syndrome with non‐invasive venous examinations in patients 6 weeks after a first episode of deep vein thrombosis , 2010, Journal of thrombosis and haemostasis : JTH.

[10]  A. Mansilha,et al.  Genetic polymorphisms and risk of recurrent deep venous thrombosis in young people: prospective cohort study. , 2005, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[11]  E. Seifried,et al.  Intrinsic clotting factors in dependency of age, sex, body mass index, and oral contraceptives: definition and risk of elevated clotting factor levels , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[12]  J. Yudkin,et al.  Determinants of Plasminogen Activator Inhibitor 1 Activity in Treated NIDDM and Its Relation to a Polymorphism in the Plasminogen Activator Inhibitor 1 Gene , 1995, Diabetes.

[13]  R. Macko,et al.  Regression of proximal deep venous thrombosis is associated with fibrinolytic enhancement. , 1997, Journal of vascular surgery.

[14]  M. Alessi,et al.  PAI-1 and the Metabolic Syndrome: Links, Causes, and Consequences , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[15]  S. Bonovas,et al.  The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. , 2008, Thrombosis research.

[16]  H. Lijnen.  Pleiotropic functions of plasminogen activator inhibitor‐1 , 2005, Journal of thrombosis and haemostasis : JTH.

[17]  J. P. Irigoyena,et al.  The plasminogen activator system : biology and regulation , 2022 .

[18]  A. Buzoianu,et al.  VKORC1 -1639 G>A Polymorphism in Romanian Patients With Deep Vein Thrombosis , 2016, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[19]  P. Ridker,et al.  Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. , 1997, Circulation.

[20]  A. Kaider,et al.  A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. , 1996, Thrombosis research.

[21]  A. V. Van rij,et al.  Prospective study of natural history of deep vein thrombosis: early predictors of poor late outcomes. , 2013, Annals of vascular surgery.

[22]  W. Renner,et al.  Role of angiotensin‐converting enzyme insertion/deletion and plasminogen activator inhibitor‐1 4G/5G gene polymorphisms in retinal vein occlusion , 2005, Journal of thrombosis and haemostasis : JTH.

[23]  E. Corrado,et al.  Residual vein thrombosis and onset of post-thrombotic syndrome: influence of the 4G/5G polymorphism of plasminogen activator inhibitor-1 gene. , 2014, Thrombosis research.

[24]  B. Wiman,et al.  4G/5G Polymorphism of PAI-1 Gene Promoter and Fibrinolytic Capacity in Patients with Deep Vein Thrombosis , 1998, Thrombosis and Haemostasis.

[25]  P. Reitsma,et al.  Resistance to Activated Protein C and Factor V Leiden as Risk Factors for Venous Thrombosis , 1995, Thrombosis and Haemostasis.

[26]  S. Kahn,et al.  Predictors of post‐thrombotic syndrome in a population with a first deep vein thrombosis and no primary venous insufficiency , 2013, Journal of thrombosis and haemostasis : JTH.

[27]  B. Binder,et al.  The 4G/5G Sequence Polymorphism in the Promoter of Plasminogen Activator Inhibitor-1 (PAI-1) Gene: Relationship to Plasma PAI-1 Level in Venous Thromboembolism , 1998, Thrombosis and Haemostasis.

[28]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[29]  D. Healy,et al.  Influence of age on venous physiologic parameters. , 1993, Journal of vascular surgery.

[30]  M. Margaglione,et al.  The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary artery disease. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[31]  S. Eichinger,et al.  Deep vein thrombosis , 2005, The Lancet.

[32]  C. Mannhalter,et al.  The 4G/4G genotype at nucleotide position −675 in the promotor region of the plasminogen activator inhibitor 1 (PAI‐1) gene is less frequent in young patients with minor stroke than in controls , 2000, British journal of haematology.

[33]  M. Prins,et al.  Residual vein thrombosis and the risk of subsequent serious complications. , 2015, Thrombosis research.

[34]  B. Jilma,et al.  Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. , 1997, Circulation.

[35]  G. Escolar,et al.  The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. , 2000, Arthritis and rheumatism.

[36]  G Leone,et al.  The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. , 1999, The New England journal of medicine.

[37]  A. Hamsten,et al.  Plasminogen Activator Inhibitor-1 4G/5G Polymorphism and Risk of Stroke: Replicated Findings in Two Nested Case–Control Studies Based on Independent Cohorts , 2005, Stroke.

[38]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[39]  F. Rosendaal.  Causes of venous thrombosis , 2016, Thrombosis Journal.

[40]  S. Kahn,et al.  Association between Thrombophilia and the Post-Thrombotic Syndrome , 2013, International journal of vascular medicine.

[41]  E. Solá,et al.  Plasminogen activator inhibitor-1 levels in severe and morbid obesity. Effect of weight loss and influence of 4G/5G polymorphism. , 2008, Thrombosis research.

[42]  M. Prins,et al.  Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism , 2002, Annals of Internal Medicine.

[43]  C. Marosi,et al.  Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients – results from the Vienna Cancer And Thrombosis Study (CATS) , 2015, Journal of thrombosis and haemostasis : JTH.

[44]  S. Haffner,et al.  Promoter (4G/5G) Plasminogen Activator Inhibitor-1 Genotype and Plasminogen Activator Inhibitor-1 Levels in Blacks, Hispanics, and Non-Hispanic Whites: The Insulin Resistance Atherosclerosis Study , 2003, Circulation.

[45]  Miss A.O. Penney.  (b) , 1974, The New Yale Book of Quotations.

[46]  A. Griesmacher,et al.  Comparison between the impact of morning and evening doses of rivaroxaban on the circadian endogenous coagulation rhythm in healthy subjects , 2016, Journal of thrombosis and haemostasis : JTH.

[47]  P. Simioni,et al.  The PAI-I gene 4G/5G Polymorphism and Deep Vein Thrombosis in Patients with Inherited Thrombophilia , 2003, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.